SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

   Biotech / MedicalGlycoGenesys GLGS (formerly SafeScience SAFS)


Previous 10 Next 10 
To: Findit who wrote (33)1/25/2005 1:26:25 AM
From: blind-geezer
   of 56
 
is this company going to bankruptcy ???
down another 10%, when will the suffering end ???

Share RecommendKeepReplyMark as Last ReadRead Replies (1)


To: blind-geezer who wrote (34)3/4/2005 2:58:45 PM
From: tuck
   of 56
 
>>BOSTON--(BUSINESS WIRE)--March 4, 2005--GlycoGenesys, Inc. (Nasdaq: GLGS - News), a biotechnology company developing carbohydrate-based drugs, today announced that it has entered into definitive agreements to close on gross proceeds of $6,500,000 from institutions in exchange for issuance of 6,500 shares of convertible, redeemable Series D Preferred Stock, currently convertible into 6,500,000 shares of common stock, and warrants to purchase 6,500,000 shares of common stock currently at $1.23. The terms of the Series D Preferred Stock and warrants will be described in a Current Report on Form 8-K that the Company will file with the Securities and Exchange Commission.

The financing will take place in two closings. In the first closing, investors will purchase $2,000,000 of Series D Preferred Stock and warrants. The second closing, for which Nasdaq rules requires receipt of shareholder approval, shall cover the remaining $4,500,000 of Series D Preferred Stock and warrants.

The Company intends to use the proceeds from this transaction primarily for funding the costs of enrolling and conducting its Phase I/II dose ranging clinical trial for GCS-100LE in multiple myeloma, funding the initiation of its Phase I/II dose ranging clinical trial for GCS-100LE in chronic lymphocytic leukemia, manufacturing drug supplies of GCS-100LE for its clinical trial needs through 2005, conducting additional analytical and pre-clinical studies, paying licensing fees and working capital for general corporate purposes.<<

snip

I'd like to see PRW facing similar cash issues. Evil grin. I'd like to see some interim data or something aside from fiscal issues. Frown.

Cheers, Tuck

Share RecommendKeepReplyMark as Last ReadRead Replies (1)


To: tuck who wrote (35)3/4/2005 3:14:30 PM
From: blind-geezer
   of 56
 
dude, is this a good thing or a bad thing ???

Share RecommendKeepReplyMark as Last ReadRead Replies (1)


To: blind-geezer who wrote (36)3/4/2005 3:29:49 PM
From: tuck
   of 56
 
Both. The bad: It's debt. The warrants put a cap on it, should good news propel the stock. If it's really good news, the cap may not be there long. The good: they're a going concern for a while. If the next round of clinical results are anything less than darn good -- i.e. sufficient to genuinely support advancement and attract a partner -- take what you have left and run. I know I will. Thank god this was a little gambling position for me.

Cheers, Tuck

Share RecommendKeepReplyMark as Last ReadRead Replies (1)


To: tuck who wrote (37)4/5/2005 5:48:47 PM
From: tuck
   of 56
 
>>BOSTON--(BUSINESS WIRE)--April 5, 2005--GlycoGenesys, Inc. (NASDAQ:GLGS - News), a biotechnology company focused on carbohydrate drug development, today announced it recently initiated a Phase I/II dose escalation clinical trial of its cancer drug candidate GCS-100LE in patients with multiple myeloma, the second most common hematologic, or blood, cancer. The first trial site is the Dana-Farber Cancer Institute in Boston. The trial will be conducted under the direction of Dr. Kenneth C. Anderson and Dr. Paul Richardson, the Principal Investigator. Dr. Richardson is the Clinical Director of the Jerome Lipper Multiple Myeloma Center at the Dana-Farber Cancer Institute and an Assistant Professor of Medicine, Harvard Medical School. Dr. Anderson is the Chief, Division of Hematologic Neoplasia at the Dana-Farber Cancer Institute and the Kraft Family Professor of Medicine, Harvard Medical School.

Both Drs. Anderson and Richardson are world-leading experts in the research of treatments for multiple myeloma. Among several important clinical studies in multiple myeloma, Drs. Anderson and Richardson were intimately involved in pre- clinical testing, trial design and human clinical trials that led to the regulatory approval of Velcade® marketed by Millennium Pharmaceuticals and Johnson and Johnson for the treatment of multiple myeloma.

About The Clinical Trial

Patients will receive GCS-100LE as a monotherapy in treatment cycles of two doses of GCS-100LE per week for 2 weeks followed by one week off therapy. If patients progress after 2 cycles or remain stable after 4 cycles, dexamethasone, a standard therapy, may be added to their treatment. Patients showing a partial or complete response on GCS-100LE as a monotherapy or GCS-100LE in combination with dexamethasone will continue on such treatment. The combination of GCS- 100LE and dexamethasone has been shown pre-clinically to have an additive effect on the killing of multiple myeloma cells.

The primary objective of the Phase I/II dose escalation study is to evaluate the safety of GCS-100LE when given to patients with relapsed or refractory multiple myeloma and to identify the recommended dose for future studies. Secondary objectives are to evaluate the response to GCS-100LE as a monotherapy and in combination with dexamethasone and determine the pharmacokinetics of GCS-100LE alone and with dexamethasone.

"I'm excited to see this trial begin. Based on our preclinical work we believe there is promise for GCS-100 to have a positive effect on patients with multiple myeloma. We look forward to contributing to the development of GCS-100," stated Dr. Richardson.

Clinical Trial Strategy For Multiple Myeloma

A Phase II/III multiple myeloma trial is planned to follow this trial. The Company will work with clinical investigators and the FDA with the aim of designing this trial as a pivotal study, assuming the data supports it.

Scientific Rationale

The scientific rationale behind initiating this clinical trial is based on pre- clinical research conducted on GCS-100LE by Dr. Anderson and his colleagues at Dana-Farber's Jerome Lipper Multiple Myeloma Center. Under Dr. Anderson's direction, the Center's researchers have pioneered new pre-clinical models to evaluate the potential of new multiple myeloma drug candidates before they enter human clinical testing. Findings from their promising research on GCS-100LE were published in an abstract in Blood and presented during a poster session at the American Society of Hematology's 2004 Annual Meeting in December.

In pre-clinical studies GCS-100LE has been shown to:

Induce cell death in multiple myeloma cells without significant toxicity against normal white blood cells.
Directly target multiple myeloma cells while in the presence of protective bone marrow cells.
Trigger cell death in multiple myeloma cells resistant to commonly used anti- cancer agents including dexamethasone, melphalan, doxorubicin, and Velcade®.
Have additive and synergistic effects when combined with caspase-activating agents dexamethasone and PK11195, respectively.
These findings provide the framework for clinical evaluation of GCS-100LE either alone or in combination with dexamethasone or other therapies to overcome drug resistance and potentially improve patient outcome in multiple myeloma.

About Multiple Myeloma (MM)

Multiple myeloma is a bone marrow cancer in which white blood cells known as plasma cells, normally responsible for the production of infection-fighting antibodies, become abnormal and are overproduced. The proliferation of these abnormal plasma cells, called myeloma cells, results in decreased production of normal blood cells and disease-fighting antibodies. This proliferation causes growth of tumors that spread to multiple sites - hence the term multiple myeloma. The decreased white blood cell production weakens the immune system and decreased red blood cell production leads to fatigue and weakness, while the myeloma tumors cause bone destruction, pain and fractures.

MM is the second most common hematologic malignancy and although the disease is predominantly a cancer among older individuals (the average age of onset is 65 to 70 years of age), recent statistics indicate both increasing incidence and onset at a younger age. In the United States, more than 50,000 individuals have MM and over 14,600 new cases of the disease are diagnosed each year. Worldwide, there are approximately 74,000 new cases and over 45,000 deaths due to multiple myeloma each year.

About Dana-Farber and The Jerome Lipper Multiple Myeloma Center

Dana-Farber Cancer Institute is a principal teaching affiliate of Harvard Medical School, a federally designated Center for AIDS Research, and a founding member of the Dana-Farber/Harvard Cancer Center (DF/HCC), a federally designated comprehensive cancer center. Providing advanced training in cancer treatment and research for an international faculty, the Institute conducts community-based programs in cancer prevention, detection, and control throughout New England, and maintains joint programs with other Boston institutions affiliated with Harvard Medical School and the Partners Health Care System, including Brigham & Women's Hospital, Children's Hospital, and Massachusetts General Hospital.

The Jerome Lipper Multiple Myeloma Center at the Dana-Farber Cancer Institute provides comprehensive, state-of-the-art care, including promising new therapies through clinical trials, to patients with multiple myeloma. In addition, the center conducts an active program of basic and clinical research aimed at improving the outcomes of patients with multiple myeloma. <<

snip

Good, but need some interim data, or some kind of results.

Cheers, Tuck

Share RecommendKeepReplyMark as Last ReadRead Replies (1)


To: tuck who wrote (38)5/4/2005 6:16:51 PM
From: tuck
   of 56
 
Paid report by a Scimitar analyst:

scimitarequity.com

Calls it a buy. Yeah, maybe now that it's utterly cratered to the point that it again has listing issues.

An NDA in multiple myeloma by 2007? Seem a little ambitious to anyone? Apparently there's some work by Dana Farber people showing GLGS compound has promise in bortezomib-refractory MM, which is indeed interesting.

Cheers, Tuck

Share RecommendKeepReplyMark as Last ReadRead Replies (1)


To: tuck who wrote (39)5/4/2005 6:34:43 PM
From: tuck
   of 56
 
Oh, right, there was a PR about all this, of course. The abstract:

>>[2456] Mitochondria and Caspase-Independent Cell-Death Triggered by GCS-100, a Novel Carbohydrate-Based Therapeutic in Multiple Myeloma (MM) Cells. Session Type: Poster Session 669-II

Dharminder Chauhan, Guilan Li, Klaus Podar, Teru Hideshima, Kenji Ishitsuka, Laurence Catley, Martin Sattler, Yu-Tzu Tai, Renate Burger, Paul Richardson, Yan Chang, Joanne Schindler, Bradley Carver, Kenneth C. Anderson (Intr. by Kenneth C. Anderson). Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA; GlycoGenesys, Inc, Boston, MA, USA

GCS-100 is a carbohydrate-based therapeutic in clinical development for the treatment of cancer. Here we show that GCS-100 directly targets MM cells and their bone marrow (BM) microenvironment. Treatment of various MM cell lines, including those resistant to conventional anti-MM agents such as, dexamethasone, melphalan, or doxorubicin, with GCS-100 triggers growth arrest and apoptosis. Examination of purified patient MM cells demonstrated similar results, without significant toxicity against normal peripheral blood mononuclear cells. Importantly, GCS-100 decreases viability of bortezomib-resistant MM patient cells. GCS-100 blocks MM cell growth induced by both adhesion to bone marrow stromal cells (BMSCs) and related cytokine secretion, thereby inhibiting growth and survival in MM cells conferred by the BM microenvironment. GCS-100 overcomes drug-resistance conferred by anti-apoptotic protein Bcl-2 and heat shock protein-27. Although GCS-100 induces MM cell death evidenced by morphological and DNA fragmentation analysis, no activation of caspases-8, -9 and -3 was noted at the IC50 dose. Conversely, the pan caspase inhibitor Z-VAD-fmk failed to abrogate GCS-100-induced apoptosis. Furthermore, GCS-100 does not alter mitochondrial membrane potential, suggesting a mitochondria- and caspase-independent cell death-signaling pathway. These data provided the rationale for combining GCS-100 with an agent that specifically triggers mitochondrial apoptotic signaling in MM cells. For example, combining a conventional agent dexamethasone, a known inducer of Smac release from mitochondria and activator of caspase-9/3 cascade, with GCS-100 shows additive anti-MM activity; and combining GCS-100 with an antagonist to mitochondrial peripheral benzodiazepine receptor PK-11195 shows synergistic anti-MM activity, associated with profound mitochondrial cell-death signaling and activation of caspase-9 and –3. Collectively, these findings lay the framework for clinical evaluation of GCS-100, either alone or in combination with dexamethasone or PK-11195, to overcome drug resistance and improve patient outcome in MM.

Abstract #2456 appears in Blood, Volume 104, issue 11, November 16, 2004<<

Cheers, Tuck

Share RecommendKeepReplyMark as Last ReadRead Replies (1)


To: tuck who wrote (40)6/15/2005 2:25:02 PM
From: tuck
   of 56
 
[GCS-100 mechanism of apoptotic action, the sequel]

>>BOSTON--(BUSINESS WIRE)--June 15, 2005-- New Discovery Revealed At The 9th International Conference On Malignant Lymphoma in Lugano, Switzerland

GlycoGenesys, Inc. (Nasdaq: GLGS - News), a biotechnology company focused on carbohydrate-based drug development, today announced that Dr. Finbarr Cotter, Professor, Barts and The London Queen Mary's School of Medicine UK, revealed how GCS-100 targets cells from CLL patients and a variety of lymphoma cell lines to induce cell death. These new findings were presented recently at the prestigious 9th International Conference on Malignant Lymphoma. The presentation and a corresponding published abstract from the conference were entitled "GCS-100 A Novel Galectin-3 Antagonist and Caspace-9 Activating Therapy For Indolent B-Cell Malignancies."

To provide a context to understand the potential commercial implications of Dr. Cotter's research, we believe it is important to know that GlycoGenesys' cancer drug candidate GCS-100 has been shown to bind to Galectin-3. Also, earlier literature demonstrates that Galectin-3 and Bcl-2 are over-expressed in a variety of lymphomas and solid tumor cancers. Moreover, GCS-100 is the first Galectin-3 inhibitor now in clinical trials for the treatment of both bloodborne and solid tumor cancers.

With this background, a summary of the new scientific findings includes:

Dr. Cotter demonstrated for the first time that Galectin-3 and Bcl-2 are co- located in malignant cell lines;
That GCS-100 blocks Galectin-3's ability to co-locate with Bcl-2 in these malignant cell lines causing targeted cell death;
And, this programmed cell death occurs through the known caspase-9 mediated cell death pathway;

Moreover, GCS-100 induced significant programmed cell death in both malignant cell lines and primary patient CLL cells with minimal effect against normal B-cells and stem cells;
And, Dr. Cotter's new data strongly supports previously published research that Galectin-3 is a valid therapeutic target to treat cancer.

Dr. Cotter stated, "These findings provide a real insight into an exciting new agent for cancer therapy as well as a greater understanding of newly emerging cancer therapy targets, namely the galectins. I look forward to being involved as an advisor in the upcoming CLL trial and reporting additional research on GCS-100 at future meetings and in publications."

Bradley J Carver, the Company's CEO and President stated, "Dr. Cotter's findings tell us how GCS-100 targets and destroys malignant lymphoma and CLL cells with minimal effect against normal B-cells and stem cells. This information is very exciting as it supports our choice of CLL as the indication of our next clinical trial and will be helpful in our partnering discussions for GCS-100."

About the Presentation

Dr. Cotter's presentation focused on new scientific discoveries about lymphoma and chronic lymphocytic leukemia (CLL) cells and their potential therapeutic relevance to GlycoGenesys' cancer drug candidate GCS-100. In newly presented data, Dr. Cotter showed for the first time that Galectin-3 and Bcl-2 are co- located in malignant lymphoma cell lines. Further and importantly, his data demonstrated in vitro that GCS-100 induced targeted cancer cell death by blocking Galectin-3's ability to co-locate with Bcl-2 in these cell lines. Moreover, the data illustrated that GCS-100 induced cancer cell death in these patient cells and cell lines through caspase-9, a well known cancer cell death pathway.

Bcl-2 and Galectin-3 are known to protect cancer cells from dying. Published literature suggests that over expression of these survival proteins is often associated with chemotherapy resistance and/or poorer clinical outcomes for cancer patients. This new data on GCS-100 provides significantly more detail of its mechanism of action in selectively targeting and inducing cell death in lymphoma cells and CLL.

Dr. Cotter underscored his previously reported data illustrating GCS-100's ability to enhance the effect of existing chemotherapeutic agents, including etoposide. Another favorable attribute of GCS-100 discussed by Dr. Cotter is its lack of myelosuppression, a negative side effect of some widely used cancer treatments. Myelosuppression is a condition in which bone marrow activity is decreased resulting in fewer red blood cells, white blood cells and platelets.

About The Conference Abstract:

Annals of Oncology, Official Journal of The European Society for medical Oncology. Volume 16, 2005 Supplement 5.

Abstract # 111, GCS-100 A Novel Galectin-3 Antagonist and Caspace-9 Activating Therapy For Indolent B-Cell Malignancies<<

The stock has sunk so low that this is good for a 20% bounce. Imagine what kind of bounce we'd see on CLINICAL results.

snip

Cheers, Tuck

Share RecommendKeepReplyMark as Last ReadRead Replies (2)


To: tuck who wrote (41)8/8/2005 4:03:47 PM
From: tuck
   of 56
 
Corporate update:

>>BOSTON--(BUSINESS WIRE)--Aug. 8, 2005--GlycoGenesys, Inc., (NASDAQ: GLGS - News), a biotechnology company focused on carbohydrate-based drug development, provided a corporate update on its cancer clinical trial programs for GCS-100, its pipeline expansion strategy and the expected timelines for its drug development programs.

SUMMARY

Today the Company announced:

The addition of a site to its initiated Phase I/II multiple myeloma trial;
Plans for its Phase I/II clinical trial in chronic lymphocytic leukemia (CLL);
A more detailed clinical development plan and timelines for GCS-100 in solid tumors and bloodborne cancers;
Efforts to establish a long-term funding relationship in 2005 to help fund its clinical trial programs and pipeline expansion
UPDATE ON 2005 GCS-100 CANCER PROGRAM

The Company's clinical program positions it to pursue approval in two indications for unmet medical needs in cancer (multiple myeloma and CLL) and starts the international regulatory process for GCS-100. This is in addition to the Company's continuing solid tumor program. The Company may also choose to apply for Fast Track designation in the U.S. for one or both bloodborne indications in the future.

Solid Tumors

GlycoGenesys' Phase I dose escalation trial for patients with advanced-stage solid tumors is enrolling patients at the sixth dose level (200mg/meter squared) planned under the protocol. This trial is currently being conducted at three clinical sites: Sharp Memorial Hospital, Clinical Oncology Research, in San Diego, California, the Arizona Cancer Center in Tucson, Arizona and the Arizona Cancer Center - Greater Phoenix Area in Scottsdale, Arizona. The Company plans to disclose preliminary results from this trial later this month.

A Phase II trial for treatment of solid tumors is planned for initiation in the second quarter of 2006. The study will be designed with the assistance of the Company's experienced Scientific Advisory Board. Preclinical efficacy studies, pharmacokinetic analyses and tumor assessment data from the current Phase I study will be carefully considered to determine the specific tumor types, dosing regimen and likely combination therapy strategy. If results of the Phase II trial are supportive, the Company plans to initiate a Phase III trial in the fourth quarter of 2007.

Multiple Myeloma

In collaboration with Dr. Kenneth Anderson and Dr. Paul Richardson of the Dana- Farber Cancer Institute, the Company designed a Phase I/II trial to study GCS- 100 in patients with relapsed or refractory multiple myeloma both alone and in combination with dexamethasone, a standard chemotherapy in multiple myeloma. This is the first clinical trial combining GCS-100 with another therapy. Dexamethasone was chosen because in vitro tests have shown GCS-100 in combination with dexamethasone to have an additive effect allowing for lower dose levels of both GCS-100 and dexamethasone to be used.

The trial was initiated at the Dana-Farber in April 2005 and is enrolling patients. The Company recently initiated a second clinical site, the Lucy Curci Cancer Center in Rancho Mirage, California. It anticipates adding three more sites to expedite patient enrollment of the trial. The Company's clinical trial timeline calls for this trial to be completed in the third quarter of 2006.

Assuming favorable data in the Phase I/II trial, a Phase II study is planned to begin in the third quarter of 2006 and be completed in the first quarter of 2008. This study will be designed to enable the Company to expand to a pivotal trial if supported by an interim review of the data. If needed to demonstrate clinical significance, a Phase III trial is planned for initiation in the third quarter of 2008.

Chronic Lymphocytic Leukemia (CLL)

The Company is pursuing CLL as an indication based on promising preclinical data including a new discovery recently presented at the prestigious 9th International Conference on Malignant Lymphoma by Dr. Finbarr Cotter of Barts Medical School in London. The first CLL clinical trial is planned to begin in the third quarter of 2005 in the U.S. with sites in the United Kingdom to follow. The protocol for this study was written in collaboration with Dr. Finbarr Cotter, Dr. Jennifer Brown, Dana-Farber Cancer Institute and Dr. Archie Prentice, Chairman British Committee for Standards in Haematology. The Company anticipates this trial will be completed in the third quarter of 2006. Pending review of the data, a pivotal Phase II/III study may be designed. This Phase II/III trial is projected to be initiated in the fourth quarter of 2006 with enrollment expected to be completed in early 2008.

PIPELINE EXPANSION

The Company is working to expand its pipeline by leveraging the potential of GCS- 100 and its analogs and by in-licensing with the goal of filing three new INDs by early 2007. Utilizing its lab in Cambridge Massachusetts the Company is conducting research on developing an orally administered version of GCS-100 and plans to file an IND for an oral formulation of GCS-100 in the third quarter of 2006. In addition, GCS-100 has shown activity in the area of angiogenesis and the Company was recently granted a patent on its use to control angiogenesis. The Company plans to work on analogs of GCS-100 in diseases in which angiogenesis plays a role with the goal of filing an IND for a non-oncology indication in the first quarter of 2007. The Company intends to out-license this analog. Finally, the Company is seeking to in-license an oncology compound with the goal of filing an IND on this compound in the first quarter of 2007.

COMMITTED TO ESTABLISHING A LONG-TERM FUNDING RELATIONSHIP IN 2005

The breadth of the Company's current trials as well as its clinical trial and pipeline plans warrant consummating a strategic funding during 2005. The Company is actively pursuing a dual track: a partnership with another pharmaceutical or biotech company, or a relationship with fundamental, long-term investors, either of which will provide long-term funding. The Company believes a strategic funding would likely benefit shareholder value, further validate its technology, and provide additional resources to conduct an expanded clinical trial program and develop its pipeline. The clinical trials planned to begin later in 2005 and pipeline development will be undertaken in conjunction with a strategic funding. The timing and/or success of these efforts cannot be predicted or assured but the Company is committed to achieving this goal expeditiously. <<

snip

Cheers, Tuck

Share RecommendKeepReplyMark as Last ReadRead Replies (1)


To: tuck who wrote (42)8/17/2005 12:55:01 PM
From: Pogeu Mahone
   of 56
 
Tuck
do you have any feelings for how this is going to turn out?

Share RecommendKeepReplyMark as Last ReadRead Replies (1)
Previous 10 Next 10